FDA Commissioner Stephen Hahn, MD, was fresh from a controversy over the authorization for emergency use of restorative plasma to treat COVID-19 when he made waves again, this time promising on Twitter that the agency would review coronavirus vaccines for the elections of November. And Pfizer executives seem to be …
Read More »
Moderna’s mRNA COVID-19 vaccine candidate was the first U.S. shot to enter late-stage testing, but that does not necessarily mean it has the brightest future of all. The high possibility of multiple emergency authorizations for coronavirus vaccines towards the end of the year speaks to a lot of competition – …
Read More »
Moderna’s coronavirus vaccine division with the US, announced last week with a $ 1.525 billion price tag, would be far more valuable if all options were exercised – and if the mRNA biotech meets an aggressive timeline for the arrival of the shot. The company will win up to a …
Read More »